Nurix Therapeutics NRIX

HealthcareMarket cap $2B1 connection

Nurix develops targeted protein degraders - drugs using the ubiquitin-proteasome system to eliminate disease-causing proteins in cancer and inflammation. Its DELigase platform designs degraders for targets previously considered undruggable. AbbVie and Gilead have partnership agreements with Nurix for its platform.

Open Nurix Therapeutics's Company Hub Simulate a merger Supply chain See it on the map

Partners 1

Strategic partnerships, joint products and alliances

Gilead SciencesHealthcare · $187BGilead collaboration on targeted protein degraders

Other Healthcare companies

Eli Lilly Johnson & Johnson AbbVie Novo Nordisk Merck UnitedHealth Thermo Fisher AstraZeneca Amgen Novartis

Embed this on your site

Show Nurix Therapeutics's network in an article or report - it updates as our data does.

<iframe src="https://vexmap.com/embed.html?co=NRIX" width="600" height="420" style="border:0;border-radius:12px;max-width:100%" title="Nurix Therapeutics on VexMap" loading="lazy"></iframe>

Preview

Relationships are compiled by VexMap from company filings, announcements and reporting, and last reviewed September 2026. Spotted something wrong? Tell us. Not investment advice.